207 related articles for article (PubMed ID: 16490841)
1. Successful adjuvant treatment of recalcitrant epidermolysis bullosa acquisita with anti-CD20 antibody rituximab.
Schmidt E; Benoit S; Bröcker EB; Zillikens D; Goebeler M
Arch Dermatol; 2006 Feb; 142(2):147-50. PubMed ID: 16490841
[No Abstract] [Full Text] [Related]
2. Epidermolysis bullosa acquisita following bullous pemphigoid, successfully treated with the anti-CD20 monoclonal antibody rituximab.
Wallet-Faber N; Franck N; Batteux F; Mateus C; Gilbert D; Carlotti A; Avril MF; Dupin N
Dermatology; 2007; 215(3):252-5. PubMed ID: 17823525
[TBL] [Abstract][Full Text] [Related]
3. Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies).
Niedermeier A; Eming R; Pfütze M; Neumann CR; Happel C; Reich K; Hertl M
Arch Dermatol; 2007 Feb; 143(2):192-8. PubMed ID: 17309999
[TBL] [Abstract][Full Text] [Related]
4. [Successful use of combined corticosteroids and rituximab in the treatment of recalcitrant epidermolysis bullosa acquisita].
Cavailhes A; Balme B; Gilbert D; Skowron F
Ann Dermatol Venereol; 2009 Nov; 136(11):795-9. PubMed ID: 19917432
[TBL] [Abstract][Full Text] [Related]
5. Successful adjuvant treatment of recalcitrant mucous membrane pemphigoid with anti-CD20 antibody rituximab.
Taverna JA; Lerner A; Bhawan J; Demierre MF
J Drugs Dermatol; 2007 Jul; 6(7):731-2. PubMed ID: 17763598
[TBL] [Abstract][Full Text] [Related]
6. Refractory epidermolysis bullosa acquisita: successful treatment with rituximab.
Saha M; Cutler T; Bhogal B; Black MM; Groves RW
Clin Exp Dermatol; 2009 Dec; 34(8):e979-80. PubMed ID: 20055876
[No Abstract] [Full Text] [Related]
7. A successful therapeutic trial of rituximab in the treatment of a patient with recalcitrant, high-titre epidermolysis bullosa acquisita.
Crichlow SM; Mortimer NJ; Harman KE
Br J Dermatol; 2007 Jan; 156(1):194-6. PubMed ID: 17199602
[No Abstract] [Full Text] [Related]
8. Treatment-resistant classical epidermolysis bullosa acquisita responding to rituximab.
Sadler E; Schafleitner B; Lanschuetzer C; Laimer M; Pohla-Gubo G; Hametner R; Hintner H; Bauer JW
Br J Dermatol; 2007 Aug; 157(2):417-9. PubMed ID: 17596155
[No Abstract] [Full Text] [Related]
9. Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris.
Faurschou A; Gniadecki R
Int J Dermatol; 2008 Mar; 47(3):292-4. PubMed ID: 18289336
[TBL] [Abstract][Full Text] [Related]
10. Rituximab in refractory autoimmune bullous diseases.
Schmidt E; Hunzelmann N; Zillikens D; Bröcker EB; Goebeler M
Clin Exp Dermatol; 2006 Jul; 31(4):503-8. PubMed ID: 16716150
[TBL] [Abstract][Full Text] [Related]
11. Premonitory epidermolysis bullosa acquisita mimicking eyelid dermatitis: successful treatment with rituximab and protein A immunoapheresis.
Kubisch I; Diessenbacher P; Schmidt E; Gollnick H; Leverkus M
Am J Clin Dermatol; 2010; 11(4):289-93. PubMed ID: 20373827
[TBL] [Abstract][Full Text] [Related]
12. Long-standing remission of recalcitrant juvenile pemphigus vulgaris after adjuvant therapy with rituximab.
Schmidt E; Herzog S; Bröcker EB; Zillikens D; Goebeler M
Br J Dermatol; 2005 Aug; 153(2):449-51. PubMed ID: 16086770
[No Abstract] [Full Text] [Related]
13. Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab).
Kong HH; Prose NS; Ware RE; Hall RP
Pediatr Dermatol; 2005; 22(5):461-4. PubMed ID: 16191003
[TBL] [Abstract][Full Text] [Related]
14. Rituximab as a treatment option for refractory endogenous anterior uveitis.
Tappeiner C; Heinz C; Specker C; Heiligenhaus A
Ophthalmic Res; 2007; 39(3):184-6. PubMed ID: 17534119
[TBL] [Abstract][Full Text] [Related]
15. A case of recalcitrant epidermolysis bullosa acquisita responsive to rituximab therapy.
McKinley SK; Huang JT; Tan J; Kroshinsky D; Gellis S
Pediatr Dermatol; 2014; 31(2):241-4. PubMed ID: 23106762
[TBL] [Abstract][Full Text] [Related]
16. Epidermolysis bullosa acquisita: diagnosis by fluorescence overlay antigen mapping and clinical response to high-dose intravenous immunoglobulin.
Campos M; Silvente C; Lecona M; Suárez R; Lázaro P
Clin Exp Dermatol; 2006 Jan; 31(1):71-3. PubMed ID: 16309488
[TBL] [Abstract][Full Text] [Related]
17. A Case Report of the Use of Rituximab and the Epidermolysis Bullosa Disease Activity Scoring Index (EBDASI) in a Patient with Epidermolysis Bullosa Acquisita with Extensive Esophageal Involvement.
Yang A; Kim M; Craig P; Murrell DF
Acta Dermatovenerol Croat; 2018 Dec; 26(4):325-328. PubMed ID: 30665483
[TBL] [Abstract][Full Text] [Related]
18. Epidermolysis bullosa acquisita.
Stein JA; Mikkilineni R
Dermatol Online J; 2007 Jan; 13(1):15. PubMed ID: 17511948
[TBL] [Abstract][Full Text] [Related]
19. Epidermolysis bullosa acquisita associated with psoriasis.
Kabashima R; Hino R; Bito T; Kabashima K; Nakamura M; Bungo O; Hashimoto T; Tokura Y
Acta Derm Venereol; 2010 May; 90(3):314-6. PubMed ID: 20526561
[No Abstract] [Full Text] [Related]
20. Successful treatment of refractory skin manifestations of systemic lupus erythematosus with rituximab: report of a case.
Uthman I; Taher A; Abbas O; Menassa J; Ghosn S
Dermatology; 2008; 216(3):257-9. PubMed ID: 18182821
[No Abstract] [Full Text] [Related]
[Next] [New Search]
